17288-40-3

Usage

Uses

Used in Pharmaceutical Industry:
5-Methoxy-1H-pyrrolo[3,2-b]pyridine is utilized as a ligand in the development of pharmaceuticals targeting various receptors and enzymes. Its unique structure allows it to interact with biological targets, potentially leading to the discovery of new therapeutic agents.
Used in Chemical Synthesis:
As a building block, 5-Methoxy-1H-pyrrolo[3,2-b]pyridine is employed in the synthesis of biologically active compounds. Its incorporation into larger molecules can enhance or modify the pharmacological properties of these compounds, contributing to the advancement of novel drug candidates.
Used in Research Applications:
In the field of scientific research, 5-Methoxy-1H-pyrrolo[3,2-b]pyridine serves as a valuable tool for studying the interactions between ligands and their respective receptors or enzymes. This can aid in understanding the mechanisms of action and potential applications in medicine.

InChI:InChI=1/C8H8N2O/c1-11-8-3-2-6-7(10-8)4-5-9-6/h2-5,9H,1H3

Upstream product

• 111795-99-4 2-(6-methoxy-3-nitropyridin-2-yl)acetonitrile 
• 5467-69-6 6-methoxy-3-nitro-2-picoline 
• 5815-08-7 tert-Butoxybis(dimethylamino)methane 
• 3598-13-8 (4-chlorophenoxy)acetonitrile 
• 28489-45-4 6-methyl-5-nitropyridin-2(1H)-one 
• 22280-62-2 6-methyl-5-nitro-2-pyridinamine 
• 22280-60-0 6-chloro-4-methyl-3-nitropyridine 
• 152562-42-0 (5-methoxy-3-nitro-pyridin-2-yl)-acetonitrile 
• 5446-92-4 2-methoxy-5-nitropyridine 
• 570386-39-9 2-Methoxy-5-Nitro-6-(2-Dimethylaminoethen-1-yl)pyridine 

Downstream Products

• 17288-55-0 3-formyl-5-methoxy-1H-pyrrolo<3,2-b>pyridine 
• 55556-41-7 5-methoxy-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole 
• 46399-68-2 1-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-3-yl)-N,N-dimethylmethanamine 
• 913983-30-9 3-iodo-5-methoxy-1H-pyrrolo[3,2-b]pyridine 
• 848357-95-9 (1-(tert-butoxycarbonyl)-5-methoxy-1H-pyrrolo[3,2-b]pyridin-2-yl)boronic acid 
• 1427032-83-4 2-(4-fluorophenyl)-5-(10-methoxy-6H-pyrido[2,3-c]pyrido[2',3':4,5]pyrrolo[1,2-c][1,3]oxazin-2-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 
• 1175014-82-0 4-[2-(3-fluoro-2-methyl-benzyl)-5-methoxy-1-phenyl-1H-pyrrolo[3,2-b]pyridine-3-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 1175014-81-9 4-(2-chloro-5-methoxy-1-phenyl-1H-pyrrolo[3,2-b]pyridine-3-carbonyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 1175014-80-8 2-chloro-5-methoxy-1-phenyl-1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid 
• 1175014-79-5 2-chloro-5-methoxy-1-phenyl-1H-pyrrolo[3,2-b]pyridine-3-carbaldehyde 
• 1175014-78-4 5-methoxy-1-phenyl-1,3-dihydro-pyrrolo[3,2-b]pyridin-2-one 
• 1175014-77-3 5-methoxy-1-phenyl-1H-pyrrolo[3,2-b]pyridine 

Relevant academic research and scientific papers

Active and Recyclable Catalytic Synthesis of Indoles by Reductive Cyclization of 2-(2-Nitroaryl)acetonitriles in the Presence of Co-Rh Heterobimetallic Nanoparticles with Atmospheric Hydrogen under Mild Conditions

A cobalt-rhodium heterobimetallic nanoparticle-catalyzed reductive cyclization of 2-(2-nitroaryl)acetonitriles to indoles has been achieved. The tandem reaction proceeds without any additives under the mild conditions (1 atm H2 and 25 °C). This procedure could be scaled up to the gram scale. The catalytic system is significantly stable under these reaction conditions and could be reused more than ten times without loss of catalytic activity.

Synthesis and antiproliferative activity of substituted 3[2-(1h-indol-3-yl)- 1,3-thiazol-4-yl]-1h-pyrrolo[3,2-b]pyridines, marine alkaloid nortopsentin analogues

A large number of indolyl-4-azaindolyl thiazoles, nortopsentin analogues, were conveniently synthesized. The antiproliferative activity of the new derivatives was examined against four human tumor cell lines with different histologic origin. Seven derivatives consistently reduced the growth of the experimental models independently of TP53 gene status and exhibited the highest activity against the malignant peritoneal mesothelioma (STO) cell line. The most active compound of this series acts as a CDK1 inhibitor, and was found to cause cell cycle arrest at G2/M phase, to induce apoptosis by preventing the phosphorylation of survivin in Thr34 and to increase the cytotoxic activity of paclitaxel in STO cells.

3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

The invention relates to 3-substituted-1H-indole, 3-substituted-1H-pyrrolo[2,3-b]pyridine, and 3-substituted-1H-pyrrolo[3,2-b]pyridine compounds of the Formula (I): or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

The invention relates to 3-substituted-1H-pyrrolo[2,3-b]pyridine, and 3-substituted-1H-pyrrolo[3,2-b]pyridine compounds of the Formula 1: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

3-Amino-1-arylpropyl azaindoles and uses thereof

The present invention provides compounds of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein p, Ar, R1, R2, R3, Ra, Rb, Rc, Rd and Re are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

PPAR ACTIVE COMPOUNDS

Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors

Several 4-azaindole and 7-azaindole dimer analogues of melatonin with a bisalkoxyalkyl spacer between the position 5 of each heterocycle were synthetized. Our aim was to investigate the influence of the spacers length on the selectivity of such compounds

Novel potent 5-HT1F receptor agonists: Structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides

Compound 1a (LY334370), a selective 5-HT1F receptor agonist (SSOFRA), inhibited dural inflammation in the neurogenic plasma protein extravasation model of migraine and demonstrated clinical efficacy for the acute treatment of migraine. Although

Polycyclic azaindole compounds

The invention relates to compounds of formula (I): wherein: G1represents an alkylene chain as defined in the description, A represents R2and R3represent hydrogen, alkyl, alkoxy or hydroxy or together form oxo, R4and R5represent hydrogen or together form aryl, R1is as defined in the description. and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.

5-HT1F agonists

The present invention relates to a compound of formula (I): or a pharmaceutical acid addition salt thereof; which is useful for activating 5-HT1freceptors and inhibiting protein extravasation in a mammal.